X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (19489) 19489
Magazine Article (59) 59
Newsletter (53) 53
Book Chapter (38) 38
Newspaper Article (14) 14
Publication (7) 7
Dissertation (6) 6
Conference Proceeding (5) 5
Book / eBook (2) 2
Book Review (2) 2
Transcript (2) 2
Streaming Video (1) 1
Web Resource (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (18505) 18505
interferon-alpha - therapeutic use (14877) 14877
science & technology (13216) 13216
life sciences & biomedicine (12867) 12867
male (10897) 10897
female (10337) 10337
middle aged (8829) 8829
adult (8403) 8403
antiviral agents - therapeutic use (7596) 7596
recombinant proteins (6941) 6941
treatment outcome (5055) 5055
hepatitis c, chronic - drug therapy (4935) 4935
ribavirin - therapeutic use (4625) 4625
aged (4539) 4539
drug therapy, combination (4137) 4137
interferon-alpha - administration & dosage (3761) 3761
gastroenterology & hepatology (3563) 3563
polyethylene glycols - therapeutic use (3529) 3529
interferon (3522) 3522
interferon-alpha - adverse effects (3380) 3380
hepatitis c (2669) 2669
hepacivirus - genetics (2622) 2622
oncology (2388) 2388
recombinant proteins - therapeutic use (2137) 2137
genotype (2114) 2114
hepatitis c - drug therapy (2033) 2033
hepatitis c virus (1842) 1842
abridged index medicus (1841) 1841
interferon alpha-2 (1830) 1830
antiviral agents - adverse effects (1785) 1785
biological response modifiers (1759) 1759
antineoplastic agents - therapeutic use (1739) 1739
adolescent (1700) 1700
antineoplastic combined chemotherapy protocols - therapeutic use (1674) 1674
immunology (1623) 1623
ribavirin (1622) 1622
animals (1608) 1608
interferon alpha (1546) 1546
hepatitis c, chronic - virology (1537) 1537
time factors (1502) 1502
infectious diseases (1457) 1457
antiviral agents - administration & dosage (1450) 1450
health aspects (1427) 1427
virology (1416) 1416
follow-up studies (1406) 1406
care and treatment (1381) 1381
viral load (1375) 1375
rna, viral - blood (1351) 1351
hepacivirus - drug effects (1278) 1278
retrospective studies (1245) 1245
pharmacology & pharmacy (1228) 1228
hematology (1185) 1185
interferon-alpha - pharmacology (1177) 1177
prospective studies (1176) 1176
ribavirin - administration & dosage (1125) 1125
prognosis (1112) 1112
hepatitis c, chronic - complications (1102) 1102
combined modality therapy (1088) 1088
hepatitis b, chronic - drug therapy (1079) 1079
hepatitis (1073) 1073
general & internal medicine (1034) 1034
medicine, general & internal (1021) 1021
drug therapy (1006) 1006
ribavirin - adverse effects (999) 999
drug administration schedule (951) 951
risk factors (920) 920
hepatitis c - therapy (913) 913
mice (910) 910
young adult (906) 906
recurrence (888) 888
polyethylene glycols - adverse effects (859) 859
polyethylene glycols - administration & dosage (856) 856
analysis (844) 844
alanine transaminase - blood (839) 839
hepacivirus - isolation & purification (827) 827
chronic disease (820) 820
dose-response relationship, drug (818) 818
child (814) 814
research (812) 812
hepatitis c - complications (806) 806
remission induction (797) 797
chronic hepatitis c (748) 748
interferon-alpha (738) 738
virus diseases (721) 721
aged, 80 and over (699) 699
medicine & public health (677) 677
immunotherapy (673) 673
immunologic factors - therapeutic use (668) 668
polyethylene glycols (663) 663
melanoma - drug therapy (646) 646
genetic aspects (638) 638
liver - pathology (638) 638
antiviral agents - pharmacology (625) 625
infections (625) 625
hepatitis c - virology (610) 610
hepatitis c, chronic - genetics (609) 609
survival rate (606) 606
survival analysis (603) 603
polymerase chain reaction (602) 602
research article (595) 595
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (17875) 17875
French (432) 432
Japanese (334) 334
German (321) 321
Chinese (304) 304
Spanish (303) 303
Russian (238) 238
Polish (125) 125
Portuguese (97) 97
Italian (85) 85
Hungarian (54) 54
Korean (34) 34
Czech (25) 25
Dutch (23) 23
Serbian (14) 14
Danish (12) 12
Swedish (10) 10
Croatian (9) 9
Hebrew (9) 9
Finnish (7) 7
Norwegian (7) 7
Ukrainian (7) 7
Slovak (6) 6
Romanian (5) 5
Turkish (5) 5
Arabic (2) 2
Bulgarian (1) 1
Slovenian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Cancer treatment reviews, ISSN 0305-7372, 11/2016, Volume 50, pp. 109 - 117
... are approved for first-line or later-line use in the treatment of patients with mRCC [1–3] . Among these agents, 1 is a monoclonal antibody targeting vascular endothelial... 
Hematology, Oncology and Palliative Medicine | Prognostic markers | Predictive markers | Sequential therapy | Overall survival | Targeted therapy | mRCC | Life Sciences & Biomedicine | Oncology | Science & Technology | Niacinamide - analogs & derivatives | Anilides - therapeutic use | Kidney Neoplasms - genetics | Bevacizumab - therapeutic use | Prognosis | Humans | Gene Expression Regulation, Neoplastic | Carcinoma, Renal Cell - genetics | Antibodies, Monoclonal - therapeutic use | Antineoplastic Agents - therapeutic use | Kidney Neoplasms - metabolism | Vascular Endothelial Growth Factor A - genetics | Sunitinib | Tumor Suppressor Proteins - genetics | Biomarkers, Tumor - metabolism | Axitinib | Everolimus - therapeutic use | Von Hippel-Lindau Tumor Suppressor Protein - genetics | Imidazoles - therapeutic use | Carcinoma, Renal Cell - drug therapy | Nuclear Proteins - genetics | Pyrroles - therapeutic use | Molecular Targeted Therapy - methods | Pyridines - therapeutic use | Histone-Lysine N-Methyltransferase - genetics | Sirolimus - analogs & derivatives | Sirolimus - therapeutic use | Receptors, CCR4 - genetics | Interferon-alpha - therapeutic use | Niacinamide - therapeutic use | Phenylurea Compounds - therapeutic use | Transcription Factors - genetics | Ubiquitin Thiolesterase - genetics | Carcinoma, Renal Cell - metabolism | Sulfonamides - therapeutic use | Pyrimidines - therapeutic use | Carcinoma, Renal Cell - secondary | Nivolumab | Sorafenib | Indoles - therapeutic use | Kidney Neoplasms - pathology | MicroRNAs - genetics | Quinolines - therapeutic use | Mutation | Kidney Neoplasms - drug therapy | Indazoles - therapeutic use | Precision Medicine - methods | Immunologic Factors - therapeutic use | Antimitotic agents | Care and treatment | Metastasis | Antineoplastic agents | Patient outcomes | Cancer | Index Medicus
Journal Article
The Medical clinics of North America, ISSN 0025-7125, 05/2012, Volume 96, Issue 3, pp. 621 - 634
Type 1 diabetes is an autoimmune disease that gradually destructs insulin-producing beta cells. Over the years, clinicians' knowledge regarding the... 
Immunosuppressants | Transplantation | Diabetes mellitus type 1 | Immunomodulators | Immunotherapies | Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Azathioprine - therapeutic use | Humans | Immunosuppressive Agents - therapeutic use | Insulin - immunology | Recombinant Fusion Proteins - therapeutic use | Antibodies, Monoclonal - therapeutic use | Fatty Acids, Unsaturated - therapeutic use | Pyrazines - therapeutic use | Secondary Prevention | Diabetes Mellitus, Type 1 - therapy | Receptors, Tumor Necrosis Factor - therapeutic use | Abatacept | Etanercept | Glutamate Decarboxylase - therapeutic use | Antilymphocyte Serum - therapeutic use | Immunoconjugates - therapeutic use | Islets of Langerhans Transplantation | Diabetes Mellitus, Type 1 - immunology | Sitagliptin Phosphate | Tertiary Prevention | Triazoles - therapeutic use | Hypoglycemic Agents - therapeutic use | Primary Prevention | Antibodies, Monoclonal, Humanized - therapeutic use | Interferon-alpha - therapeutic use | Immunoglobulin G - therapeutic use | Niacinamide - therapeutic use | Rituximab | Vitamins - therapeutic use | Cyclosporine - therapeutic use | Interleukin 1 Receptor Antagonist Protein - therapeutic use | Diet | Venoms - therapeutic use | Peptide Fragments - therapeutic use | Vitamin D - therapeutic use | Chaperonin 60 - therapeutic use | Insulin - therapeutic use | Peptides - therapeutic use | Antibodies, Monoclonal, Murine-Derived - therapeutic use | Hypoglycemic Agents - immunology
Journal Article
2005, Volume 6, Issue 2, 11
Book Review
Gastroenterology (New York, N.Y. 1943), ISSN 0016-5085, 05/2012, Volume 142, Issue 6, pp. 1324 - 1334.e3
With the development of effective therapies against human immunodeficiency virus (HIV), hepatitis C virus (HCV) infection has become a major cause of morbidity... 
Gastroenterology and Hepatology | Drug Interaction | HCV | Treatment | HIV | Liver Disease | Gastroenterology & Hepatology | Life Sciences & Biomedicine | Science & Technology | Recombinant Proteins - therapeutic use | Coinfection | Antiviral Agents - pharmacokinetics | HIV Infections - epidemiology | Humans | Hepatitis C, Chronic - etiology | Male | Polyethylene Glycols - therapeutic use | Oligopeptides - therapeutic use | Serine Proteinase Inhibitors - therapeutic use | Tenofovir | Deoxycytidine - therapeutic use | Drug Interactions | Homosexuality, Male | Adenine - therapeutic use | Lamivudine - therapeutic use | Anti-HIV Agents - therapeutic use | Dideoxynucleosides - therapeutic use | Hepatitis C, Chronic - epidemiology | Drug Therapy, Combination | Raltegravir Potassium | Substance Abuse, Intravenous - complications | Emtricitabine | Liver Diseases - virology | Antiviral Agents - pharmacology | Adenine - analogs & derivatives | Drug Administration Schedule | Organophosphonates - therapeutic use | Proline - analogs & derivatives | Antiviral Agents - therapeutic use | Liver Diseases - prevention & control | Ribavirin - therapeutic use | Interferon-alpha - therapeutic use | Pyrrolidinones - therapeutic use | Treatment Outcome | Hepatitis C, Chronic - drug therapy | Disease Progression | Proline - therapeutic use | HIV Infections - etiology | Liver Cirrhosis - virology | Antiviral Agents - adverse effects | HIV Infections - drug therapy | Deoxycytidine - analogs & derivatives | Antiviral agents | Medical colleges | Care and treatment | Liver diseases | Comorbidity | Drug interactions | Mortality | Development and progression | Biological response modifiers | HIV (Viruses) | Hepatitis | Protease inhibitors | Proteases | Hepatitis C virus | Hepatitis C | Health aspects | HIV infection | Index Medicus | Abridged Index Medicus
Journal Article
Journal Article
Gastroenterology (New York, N.Y. 1943), ISSN 0016-5085, 06/2014, Volume 146, Issue 7, pp. 1669 - 1679.e3
Background & Aims Simeprevir is an oral, once-daily inhibitor of hepatitis c virus (HCV) protease NS3/4A. We investigated the safety and efficacy of simeprevir... 
Gastroenterology and Hepatology | Drug | Chronic Hepatitis C | DAA | PROMISE | Gastroenterology & Hepatology | Life Sciences & Biomedicine | Science & Technology | Recombinant Proteins - therapeutic use | Recurrence | Simeprevir | Hepatitis C - drug therapy | Humans | Middle Aged | Hepacivirus - genetics | Polyethylene Glycols - adverse effects | Male | RNA, Viral - blood | Recombinant Proteins - adverse effects | North America | Polyethylene Glycols - therapeutic use | Viral Load | Young Adult | Time Factors | Hepatitis C - blood | Protease Inhibitors - adverse effects | Adult | Female | Drug Therapy, Combination | Protease Inhibitors - therapeutic use | Hepacivirus - drug effects | Double-Blind Method | Antiviral Agents - therapeutic use | Europe | Ribavirin - therapeutic use | Interferon-alpha - therapeutic use | Treatment Outcome | Biomarkers - blood | Hepatitis C - diagnosis | Hepacivirus - enzymology | Sulfonamides - therapeutic use | Asia | Ribavirin - adverse effects | Antiviral Agents - adverse effects | Heterocyclic Compounds, 3-Ring - adverse effects | Heterocyclic Compounds, 3-Ring - therapeutic use | Sulfonamides - adverse effects | Hepacivirus - growth & development | Viral Nonstructural Proteins - metabolism | Aged | Interferon-alpha - adverse effects | Viral Nonstructural Proteins - antagonists & inhibitors | Medical colleges | Care and treatment | Proteases | Interferon alpha | Clinical trials | Product development | Genetic aspects | Biological response modifiers | Hepatitis C virus | Hepatitis C | Health aspects | Ribavirin | Index Medicus | Abridged Index Medicus | Life Sciences
Journal Article
European Urology, ISSN 0302-2838, 2014, Volume 68, Issue 3, pp. 516 - 522
Abstract Background Limited data exist on the economic consequences of implementing targeted therapy (TT) for metastatic renal cell carcinoma (RCC) in a... 
Urology | Metastatic renal cell carcinoma | Economic analysis | Population-based | Observational | National | Targeted therapy | Cost analysis | Implementation | Life Sciences & Biomedicine | Urology & Nephrology | Science & Technology | Bevacizumab - therapeutic use | Everolimus - economics | Radiotherapy - economics | Humans | Middle Aged | Niacinamide - economics | Male | Antineoplastic Agents - therapeutic use | Efficiency | Employment - economics | Aged, 80 and over | Sirolimus - economics | Indoles - economics | Bevacizumab - economics | Costs and Cost Analysis | Protein Kinase Inhibitors - economics | Niacinamide - therapeutic use | Antineoplastic Agents - economics | Carcinoma, Renal Cell - economics | Indoles - therapeutic use | Ambulatory Care - economics | Phenylurea Compounds - economics | Drug Costs | Niacinamide - analogs & derivatives | Fluorouracil - economics | Interleukin-2 - economics | Interleukin-2 - therapeutic use | Immunologic Factors - economics | Fluorouracil - therapeutic use | Neoplasm Metastasis - drug therapy | Angiogenesis Inhibitors - therapeutic use | Adult | Angiogenesis Inhibitors - economics | Everolimus - therapeutic use | Female | Registries | Pyrroles - economics | Carcinoma, Renal Cell - drug therapy | Pyrroles - therapeutic use | Sirolimus - analogs & derivatives | Sirolimus - therapeutic use | Radiography - economics | Interferon-alpha - therapeutic use | Interferon-alpha - economics | Phenylurea Compounds - therapeutic use | Kidney Neoplasms - economics | Health Care Costs | Protein Kinase Inhibitors - therapeutic use | Carcinoma, Renal Cell - secondary | Denmark | Kidney Neoplasms - pathology | Aged | Kidney Neoplasms - drug therapy | Hospitalization - economics | Immunologic Factors - therapeutic use | Economic aspects | Metastasis | Carcinoma, Renal cell | Index Medicus
Journal Article
The Lancet (British edition), ISSN 0140-6736, 11/2014, Volume 384, Issue 9956, pp. 1756 - 1765
Journal Article